Confo Therapeutics announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. Confo will apply its proprietary ConfoBody technology to stabilize the selected GPCRs in their disease-relevant conformations, which will then be used as antigens to enable antibody discovery and development. Confo will be entitled to upfront payments, milestones, and tiered royalties on net product sales.